Intarcia Therapeutics is developing a continuous subcutaneous delivery system for the treatment of Type 2 diabetes. The RTP location discovers and develops peptide therapeutic drugs to augment Intarcia's drug delivery platform.
Company Location
6 Davis Drive
Research Triangle Park
NC
27709
P.O. Box 14230
Research Triangle Park
NC
27709
Phone
(919) 282-3801
County
Region
Company Details
Company type
Year founded
2015
Employment range in NC
US headquarters
Massachusetts
Global headquarters
United States
Primary site activity
All company activities
Core capabilities
Products under development
ITCA 650 (type 2 diabetes, regulatory approval stage); ITCA 349 + ITCA 650 (obesity, preclinical development stage)